ERBB2 and invasive breast carcinoma: Specifically, we assessed whether ER/PR/HER2 subtype and TNM stage of invasive breast carcinoma had significant impact on overall survival in a cohort of 232 elderly Caucasian female patients (≥70 y/o) from our institution at the 10 year interval (January 1998–July 2008), with 1 August 2013 as the last day of follow-up.